Commentary|Videos|January 13, 2023
Adverse Events Seen With Combination Lenvatinib and Pembrolizumab for Recurrent Endometrial Cancer
Kimberly A. Spickes, CNP, details the adverse events she sees with combination lenvatinib and pembrolizumab treatment for recurrent endometrial cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
For Gynecologic Cancer Awareness Month, Dr. Eleonora Teplinsky outlines emerging treatment toxicities, patient advocacy, and health equity.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Oncology Nurse Shares Insights From Her Stage 4 Breast Cancer Journey
2
Reframing Nurse Fatigue as Systemic Safety Risk
3
Psychedelic Medicine in Cancer Care: What Nursing Teams Need to Know
4
TURBT and Adjuvant Intravesical Therapy Options
5